Our studies demonstrated the first evidence that combination of the PARP inhibitors and the arsenic compound, which individually have poor therapeutic effects for HR-proficient ovarian cancer, show a greatly synergistic impact on this specific type of ovarian cancer. This evidence concerns the gene PARP1 and ovarian carcinoma.